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Abstract
IMPORTANCE—Hypothermia at 33.5°C for 72 hours for neonatal hypoxic ischemic 
encephalopathy reduces death or disability to 44% to 55%; longer cooling and deeper cooling are 
neuroprotective in animal models.
OBJECTIVE—To determine if longer duration cooling (120 hours), deeper cooling (32.0°C), or 
both are superior to cooling at 33.5°C for 72 hours in neonates who are full-term with moderate or 
severe hypoxic ischemic encephalopathy.
DESIGN, SETTING, AND PARTICIPANTS—Arandomized, 2 × 2 factorial design clinical 
trial performed in 18 US centers in the Eunice Kennedy Shriver National Institute of Child Health 
and Human Development (NICHD) Neonatal Research Network between October 2010 and 
November 2013.
INTERVENTIONS—Neonates were assigned to 4 hypothermia groups; 33.5°C for 72 hours, 
32.0°C for 72 hours, 33.5°C for 120 hours, and 32.0°C for 120 hours.
MAIN OUTCOMES AND MEASURES—The primary outcome of death or disability at 18 to 
22 months is ongoing. The independent data and safety monitoring committee paused the trial to 
evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel thrombosis and bleeding, and 
death in the neonatal intensive care unit [NICU]) after the first 50 neonates were enrolled, then 
after every subsequent 25 neonates. The trial was closed for emerging safety profile and futility 
analysis after the eighth review with 364 neonates enrolled (of 726 planned). This report focuses 
on safety and NICU deaths by marginal comparisons of 72 hours’ vs 120 hours’ duration and 
33.5°C depth vs 32.0°C depth (predefined secondary outcomes).
RESULTS—The NICU death rates were 7 of 95 neonates (7%) for the 33.5°C for 72 hours 
group, 13 of 90 neonates (14%) for the 32.0°C for 72 hours group, 15 of 96 neonates (16%) for the 
33.5°C for 120 hours group, and 14 of 83 neonates (17%) for the 32.0°C for 120 hours group. The 
adjusted risk ratio (RR) for NICU deaths for the 120 hours group vs 72 hours group was 1.37 
(95% CI, 0.92–2.04) and for the 32.0°C group vs 33.5°C group was 1.24 (95% CI, 0.69–2.25). 
Safety outcomes were similar between the 120 hours group vs 72 hours group and the 32.0°C 
group vs 33.5°C group, except major bleeding occurred among 1% in the 120 hours group vs 3% 
in the 72 hours group (RR, 0.25 [95% CI, 0.07–0.91]). Futility analysis determined that the 
probability of detecting a statistically significant benefit for longer cooling, deeper cooling, or 
both for NICU death was less than 2%.
CONCLUSIONS AND RELEVANCE—Among neonates who were full-term with moderate or 
severe hypoxic ischemic encephalopathy, longer cooling, deeper cooling, or both compared with 
hypothermia at 33.5°C for 72 hours did not reduce NICU death. These results have implications 
for patient care and design of future trials.
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Hypoxic ischemic encephalopathy due to acute perinatal asphyxia is an important cause of 
childhood neurodevelopmental deficits among infants who were born at full-term. Five 
randomized clinical trials of induced hypothermia at 33.0°C to 34.0°C for 72 hours have 
demonstrated a decrease in death or disability up to 24 months of age.1–7 This 
neuroprotection continues to childhood8–10; however, the rate of death or disability in the 
cooled group remains high (range, 44%–55%).1–7
Preclinical animal studies have demonstrated that brain injury following hypoxic ischemia 
continues and evolves over days and weeks after the initial injury. Deeper cooling compared 
with normothermia has been noted to minimize brain swelling, preserve cerebral energy 
metabolism, and suppress oxidative metabolism, and longer cooling may protect against 
apoptosis and inflammation initiated during reperfusion.11–17 These studies suggest that 
cooling below 33.5°C and beyond 72 hours may provide greater neuroprotection.
Methods
The study protocol was approved by the institutional review board at each site. Written 
informed consent was obtained from a parent or guardian. This study was a multicenter 
randomized clinical trial of whole-body hypothermia among infants who were born at full-
term with moderate or severe hypoxic ischemic encephalopathy to evaluate the safety and 
effectiveness of deeper cooling, longer cooling, or both. This study was conducted at all the 
18 US sites participating in the Eunice Kennedy Shriver National Institute of Child Health 
and Human Development (NICHD) Multicenter Neonatal Research Network between 
October 20, 2010, and November 27, 2013. RTI International (trade name for the Research 
Triangle Institute) was the data coordinating center for the Neonatal Research Network.
Criteria for eligibility and details of cooling and rewarming were similar to the first NICHD 
hypothermia randomized clinical trial.2 Each principal investigator certified additional 
neonatologists to perform the neurological examinations, and a training session for research 
personnel was held to standardize study procedures.2
Neonates were screened for eligibility if they had a gestational age of at least 36 weeks and 
were admitted to the neonatal intensive care unit (NICU) within 6 hours of birth with either 
poor respiratory effort at birth, a need for resuscitation, or a diagnosis of encephalopathy.
Neonates were evaluated according to physiological criteria and subsequently by a 
neurological examination.2 Eligibility criteria included a pH of 7.0 or less or a base deficit of 
16 mmol/L or more in a sample of umbilical cord blood or any blood during the first hour 
after birth. If, during this interval, a pH was between 7.01 and 7.15, a base deficit was 
between 10 mmol/L and 15.9 mmol/L, or a blood gas was not available, additional criteria 
were required. These included an acute perinatal event (eg, late or variable decelerations, 
cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage, or acute 
cardiorespiratory arrest) and either a 10-minute Apgar score of 5 or less or assisted 
ventilation initiated at birth and continued for at least 10 minutes.
Once these criteria were met, all neonates underwent a standardized neurological 
examination. Neonates were candidates for the study when seizures or moderate or severe 
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encephalopathy was present.2 Encephalopathy was defined as the presence of either 
moderate or severe signs in at least 3 of the following 6 categories: (1) level of 
consciousness (moderate is lethargic, severe is stupor or coma), (2) spontaneous activity 
(moderate is decreased activity, severe is no activity), (3) posture (moderate is distal flexion 
or complete extension, severe is decerebrate), (4) tone (moderate is hypotonia, severe is 
flaccid), (5) primitive reflexes (moderate is a weak suck [or incomplete Moro reflex], severe 
is an absent suck [or absent Moro reflex]), and (6) autonomic nervous system; either pupils 
(moderate is constricted, severe is deviated, dilated, or nonreactive to light), heart rate 
(moderate is bradycardia, severe is variable heart rate), or respiration (moderate is periodic 
breathing, severe is apnea). The number of moderate or severe signs determined the extent 
of the encephalopathy; if signs were equally distributed, the designation was based on the 
level of consciousness. Exclusion criteria were an inability to randomize within 6 hours of 
birth, a major congenital abnormality, severe growth restriction (birth weight <1800 g), a 
core temperature less than 32.5°C for at least 2 hours at the time of random assignment, and 
refusal of consent by a parent or an attending neonatologist; moribund neonates for whom 
no further treatment was planned also were excluded.
Treatment
Neonates were randomly assigned by telephone by the data coordinating center. 
Assignments were stratified according to center and level of encephalopathy (moderate or 
severe) in a 2 × 2 factorial design to 33.5°C or 32.0°C and to 72 hours or 120 hours. 
Assignments were generated by a random, permuted block algorithm with a block size of 4 
or 8. As cooling for neonatal hypoxic ischemic encephalopathy was usual care in all sites, 
clinical cooling to 33.5°C was initiated when the neonate met criteria for cooling while trial 
consent was being sought.
Neonates were placed on a blanket, 25 in × 33 in (64 cm × 84 cm), precooled to 5°C 
(Blanketrol II Hyper-Hypothermia system, Cincinnati Sub-Zero). A second blanket, 25 in × 
64 in (64 cm × 163 cm), was attached to the cooling system. Water circulated 
simultaneously through both blankets to diminish the variability in the esophageal 
temperature.2 An esophageal probe was inserted and the core temperature was lowered to 
33.5°C by the blanket’s servomechanism in both 33.5°C study groups. To dampen overshoot 
during induction of cooling in the 32.0°C groups, the esophageal temperature was initially 
lowered to 33.5°C and, once stable for15 minutes at this temperature, lowered further to 
32.0°C. Neither an overhead warmer nor any other heat source was used during cooling. 
Abdominal wall skin temperature was monitored with a skin probe by means of either the 
radiant warmer (with the heater turned off) or a temperature-monitoring unit (Mon-a-therm, 
Mallinckrodt Medical). Esophageal and skin temperatures were monitored continuously and 
recorded every 15 minutes for the first 4 hours, every hour for the next 8 hours, and every 4 
hours during the remaining period of cooling.
After completing either 72 or 120 hours of hypothermia, the set point of the automatic 
control of the cooling system was increased by 0.5°C per hour until the esophageal 
temperature reached 36.5°C to 37.0°C for 4 hours. The esophageal probe was removed, and 
skin temperature was used to control the radiant warmer. If the skin and set point 
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temperature remained low when the esophageal probe was removed, the warmer control 
temperature was set at 0.5°C higher than the skin temperature and was increased 0.5°C 
every hour until the warmer set point reached 36.5°C. Temperatures were monitored for the 
first 10 days and hyperthermia treated as per usual care at the center. Blood gas 
determinations were corrected for body temperature. Neonates received the center’s routine 
clinical care, including monitoring of vital signs and surveillance for organ dysfunction. 
Information on the race of the neonate was obtained by maternal interview to evaluate 
distribution across study groups.
Monitoring of Study
An independent data and safety monitoring committee (DSMC) appointed by the director of 
the NICHD monitored interim data and evaluated safety. As specified in the protocol, the 
study was paused for evaluation of safety (head sonograms for thrombosis or hemorrhage) 
after the first 50 neonates were enrolled. Once approved for resumption, safety reviews were 
planned after every 25 neonates were enrolled, with the data coordinating center to conduct 
these interim safety analyses and convey them to the DSMC if any safety concerns were 
apparent.
Outcomes
The primary outcome was death or disability (moderate or severe) at 18 to 22 months.18 
Data collection at these ages has not yet been completed and will be reported later. The 
NICHD Neonatal Research Network steering committee of principal investigators decided 
to report the secondary outcomes during hospitalization because of the implications of the 
results for patient care and the design of future trials. Secondary outcomes reported here 
include deaths in the NICU, number of neonates with support withdrawn, frequency of 
adverse events, and clinical seizures. Adverse events monitored included cardiac arrhythmia, 
persistent acidosis, major vessel thrombosis or bleeding, and alteration of skin integrity 
(eTable 1 in the Supplement). Other adverse events (eTable 2 in the Supplement) and 
hospital outcomes were predefined. Any equipment malfunction that caused interruption of 
cooling was noted. All serious adverse events were reported within 72 hours to the data 
center and site institutional review board per local guidelines.
Statistical Analysis
Sample size calculations assumed that there were no large statistical interactions between 
depth and duration of cooling. The primary goal was the marginal comparison of (1) cooling 
to 33.5°C vs 32.0°C and (2) cooling for 72 hours vs 120 hours. A requirement for a sample 
size of 726 neonates (363 per marginal group comparison) was based on a 2-tailed α of .05, 
a statistical power of 80%, a 5% loss to follow-up, and a comparison of death or disability of 
37.5% and 27.5% in the 2 marginal comparative groups (based on assumed outcome rates of 
45% in the 33.5°C for 72 hours group, 30% in the 32.0°C for 72 hours and 33.5°C for 120 
hours groups, and 25% in the 32.0°C for 120 hours group). The outcome rate of death or 
moderate or severe disability at 18 months of age of 45% for infants cooled in the 33.5°C for 
72 hours group is based on our first trial.2
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All data analyses were performed according to the intention-to-treat principle. There was no 
missing data for safety outcomes and minimal missing data for in-hospital outcomes, except 
bradycardia (190 missing in-hospital outcomes), which was not collected for the entire study 
period. The statistical software used was SAS (SAS Institute), version 9.3.
Maternal and neonatal variables were compared using the Fisher exact test for categorical 
variables, and the median or Wilcoxon 2-sample t test for continuous variables. Binary (yes 
or no) safety and other in-hospital outcomes were assessed using generalized estimating 
equations models for binary data, using a log link, to obtain adjusted relative risk estimates 
for the treatment effect adjusted for level of encephalopathy at random assignment, while 
accounting for any intracenter correlations in the outcomes. Continuous outcomes were 
similarly assessed using linear regression accounting for intracenter correlations, with log 
transformations used wherever necessary. To account for differential exposure periods, 
safety outcomes assessed during the intervention were compared between the 72 hours and 
120 hours groups using Poisson regression in a generalized estimating equations framework 
to model the number of such events that occurred during the intervention, with an offset for 
the exposure time (3 days for the 72 hours group and 5 days for the 120 hours group), while 
adjusting for level of encephalopathy and intracenter correlation. Treatment interactions 
between the 2 factors (deeper and longer cooling) in this factorial design and in-hospital 
mortality also were assessed. All reported P values are 2-sided and not adjusted for multiple 
comparisons. A P value less than .05 was considered significant. Stopping rules for safety in 
the form of Pocock bounds19 were calculated to reflect the number of planned interim safety 
looks. Interim futility analyses requested by the DSMC were conducted by estimating the 
conditional power to detect a statistically significant treatment effect, given the available 
data, and assuming the hypothesized effect size for the unobserved data.
Results
The study was initiated on October 20, 2010. As specified in the protocol, patient accrual 
was paused from August 6, 2011, to September 15, 2011, after 50 neonates were enrolled 
and head sonograms evaluated for the presence of thrombosis or hemorrhage. The DSMC 
concluded that the trial should continue. The DSMC requested performance of head 
sonograms for the next 50 neonates. In addition, the DSMC requested data collection on 
bradycardia (sustained heart rate of <70 beats/min). At the third DSMC review, after 100 
neonates were enrolled, the DSMC determined that head sonogram monitoring could cease 
(no safety concerns, particularly thrombosis) and recommended the study move forward. At 
the fourth review, detailed narratives were requested on all in-hospital deaths. The study 
continued following the next 3 DSMC reviews. At the eighth review on November 27, 2013, 
after 364 neonates were enrolled, although the interim safety data did not satisfy the 
prespecified safety stopping bounds, upon review of the emerging safety profile and the 
futility analyses, the DSMC recommended to the director of NICHD that the trial be closed 
to further enrollment.
At study closure, 1261 neonates were screened, 514 were eligible, and 364 were enrolled 
(Figure 1). One hundred eighty five neonates were assigned to the 72 hours group and 179 to 
the 120 hours group; 191 were assigned to the 33.5°C group and 173 to the 32.0°C group.
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Maternal and Neonatal Characteristics
Baseline maternal and neonatal characteristics were similar in the 72 hours and 120 hours 
groups and the 33.5°C and 32.0°C groups, except that among the 33.5°C and the 32.0°C 
groups, birth weight was higher in the 32.0°C group compared with the 33.5°C group, P = .
02 (Table 1).
NICU Deaths
Mortality in the NICU was 7% (7 of 95 neonates) for the 33.5°C for 72 hours group, 14% 
(13 of 90 neonates) for the 32.0°C for 72 hours group, 16% (15 of 96 neonates) for the 
33.5°C for 120 hours group, and 17% (14 of 83 neonates) for the 32.0°C for 120 hours 
group (Figure 2).
There were20 deaths of 185 neonates (11%) in the 72 hours group compared with 29 deaths 
of 179 neonates (16%) in the 120 hours group (Table 2), and the number of neonates for 
whom support was withdrawn was 15 of 20 neonates (75%) in the 72 hours group compared 
with 26 of 29 neonates (90%) in the 120 hours group. There were 22 deaths of 191 neonates 
(12%) in the 33.5°C group compared with 27 deaths of 173 neonates (16%) in the 32.0°C 
group, and the number of neonates for whom support was withdrawn was 19 of 22 (86%) in 
the 33.5°C group compared with 22 of 27 (81%) in the 32.0°C group. Support was 
withdrawn prior to the end of the designated cooling period for 1 neonate in the 33.5°C for 
72 hours group, 1 neonate in the 32.0°C for 72 hours group, 6 neonates in the 33.5°C for 120 
hours group, and 9 neonates in the 32.0°C for 120 hours group. The causes of death for the 7 
neonates in the 33.5°C for 72 hours group were asphyxia brain injury (5 neonates), 
persistent pulmonary hypertension (1 neonate), and other causes (1 neonate). For the 13 
neonates in the 32.0°C for 72 hours group, causes of death included asphyxia brain injury (7 
neonates), multiorgan failure (2 neonates), sepsis (1 neonate), and other (3 neonates). In the 
33.5°C for 120 hours group, the causes of death among 15 neonates were asphyxia brain 
injury (7 neonates), multiorgan failure (6 neonates), persistent pulmonary hypertension (1 
neonate), and other causes (1 neonate). For the 32.0°C for 120 hours group, the causes of 
death for the 14 neonates were asphyxia brain injury (5 neonates), multi-organ failure (4 
neonates), persistent pulmonary hypertension (1 neonate), pneumonia (1 neonate), and other 
causes (3 neonates).
Among neonates with moderate hypoxic ischemic encephalopathy, death in the NICU 
occurred in 6 of 144 neonates (4%) in the 72 hours group compared with 11 of 136 neonates 
(8%) in the 120 hours group and in 10 of 152 neonates (7%) in the 33.5°C group compared 
with 7 of 128 neonates (5%) in the 32.0°C group. Among neonates with severe hypoxic 
ischemic encephalopathy, deaths in the NICU occurred in 14 of 41 neonates (34%) in the 72 
hours group compared with 18 of 43 neonates (42%) in the 120 hours group and in 12 of 39 
neonates (31%) in the 33.5°C group compared with 20 of 45 neonates (44%) in the 32.0°C 
group.
The NICU mortality rates for the 120 hours and 72 hours groups were not significantly 
different (16% for 120 hours group vs 11% for 72 hours group, P = .12); the rates for the 
32.0°C group vs the 33.5°C group (16% for 32.0°C group vs 12% for 33.5°C group, P = .47) 
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were also not significantly different. The adjusted risk ratio for NICU mortality for the 120 
hours group vs 72 hours group was 1.37 (95% CI, 0.92–2.04) and for the 32.0°C group vs 
33.5°C group was 1.24 (95% CI, 0.69–2.25, Table 2).
Extracorporeal membrane oxygenation (ECMO) was selected post hoc by the DSMC for 
evaluating safety based on reports received from participating centers; the outcome of death 
or ECMO was not associated with length or depth of cooling following adjusted analysis; 
for the 120 hours group vs 72 hours group the risk ratio was 1.33 (95% CI, 0.96–1.83, P = .
09) and for the 32.0°C group vs 33.5°C group was 1.35 (95% CI, 0.83–2.19, P = .22). There 
was no interaction between depth and duration of cooling for in-hospital mortality adjusted 
for level of encephalopathy and center (P = .21).
Futility analysis revealed that the probability of detecting a statistically significant treatment 
benefit of longer or deeper cooling for in-hospital mortality was less than 2%.
Safety
Predefined safety events during study intervention were similar in the 72 hours and 120 
hours groups and the 33.5°C and 32.0°C groups, except that among the 72 hours and the 120 
hours groups, the frequency of major bleeding was higher in the 72 hours group compared 
with the 120 hours group (3% for 72 hours group vs 1% for 120 hours group, P = .04, Table 
2). The temperature profile of the 4 groups is shown in Figure 3.
During the hospital course, defined as the period between birth and death or discharge, in the 
120 hours group compared with the 72 hours group, the incidence of arrhythmia (7% for 120 
hours group vs 1% for 72 hours group, P = .02) and anuria (9% for 120 hours group vs 3% 
for 72 hours group, P = .01) were higher and hospital stay was longer (mean [SD], 26.4 days 
[34.1] for 120 hours group vs 21.6 days [15.3] for 72 hours group, P = .002). In the 32.0°C 
group compared with the 33.5°C group, a higher incidence of bradycardia (23% for 32.0°C 
group vs 1% for 33.5°C group, P = <.001), inhaled nitric oxide (34% for 32.0°C group vs 
24% for 33.5°C group, P = .03) and ECMO (9% for 32.0°C group vs 4% for 33.5°C group, 
P = .005), and moredays of oxygen (mean [SD], 8.8 [8.5] for 32.0°C group vs 8.0 [9.7] for 
33.5°C group, P = .02), were noted (Table 3).
Discussion
Hypothermia for 72 hours duration to a depth of 33.0°C to 34.0°C is now usual care for 
neonates who are full-term with moderate or severe encephalopathy.20 This study of whole-
body hypothermia to an esophageal temperature of 32.0°C or continued for 120 hours was 
designed to evaluate potential benefit of longer cooling, deeper cooling, or both. The trial 
was closed to patient enrollment because of safety and futility concerns. Had it been 
continued to its full sample size, the likelihood of this trial favoring longer cooling, deeper 
cooling, or both was found to be small. The NICU mortality rates for the deeper or longer 
cooling groups were not less than that of the usual care group; the risk ratios and upper 
bound of the 95% CIs of greater than 2 suggest deeper or longer cooling may be associated 
with an increase in mortality. Longer duration of cooling was associated with more 
arrhythmia and anuria and longer hospital days, whereas deeper cooling was associated with 
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higher use of inhaled nitric oxide therapy, ECMO, more days of oxygen, and higher 
incidence of bradycardia. The primary outcome evaluations of this trial are still ongoing; we 
wish to report these safety data at the present time to dissuade drifts in adherence to 
established protocols of hypothermia for neonatal hypoxic ischemic encephalopathy.
The NICU mortality rate for neonates assigned to the 33.5°C for 72 hours group was 7%; 
this rate is unexpectedly low.2 The mortality rates in the longer and deeper cooling groups 
(14%–17%) were similar to that in the cooled group of our previous trial (19%).2 
Comparisons with other trials are limited because NICU mortality data are not provided for 
these trials.1,3–5 The eligibility criteria for this trial were the same as our previous trial and 
neonates who were overcooled were excluded. However, the rate of severe encephalopathy 
was lower in this trial than among cooled neonates in our first trial (23% in current trial vs 
32% in the previous trial), and the neonates in this trial appeared less critically ill at 
enrollment with lower base deficit, less intubation at birth, and lower frequency of seizures.2 
In this study there was a higher frequency of maternal diabetes than our first trial2 and 
neonates in the 32.0°C group had a higher birth weight than neonates in the 33.5°C group; it 
has been reported that larger neonates are more difficult to cool than smaller neonates.21,22 
Last, in this study, any elevations of temperature following rewarming were treated 
according to the study protocol, unlike in the previous study.2 Elevations of temperature are 
associated with a higher mortality rate and a higher disability rate in infancy and childhood 
among neonates with hypoxic ischemic encephalopathy.23,24
In this study, cooling to 32.0°C was associated with significantly more inhaled nitric oxide 
and ECMO therapy. Our study protocol did not include ECMO as an adverse event because 
ECMO was rarely used in the early trials.1–6 A previous report noted an increased risk of 
pulmonary hypertensive crisis requiring ECMO among neonates undergoing hypothermia 
for hypoxic ischemic encephalopathy.25 Extracorporeal membrane oxygenation has not been 
uniformly used in this population; however, this appears to be changing. A recent meta-
analyses of 4 trials reported risk ratios of 1.36 (95% CI, 0.94–1.97) for pulmonary 
hypertension with hypothermia of 33.0° to 34.0°C, whereas 3 trials noted no significant 
effect of hypothermia on inhaled nitric oxide therapy.7 In an observational study of neonatal 
hypoxic ischemic encephalopathy where 29 neonates were treated with whole-body 
hypothermia to a core temperature of 30.0°C to 33.0°C and28 neonates cooled to a 
temperature of 33.0°C to 34.0°C, pulmonary function was similar in the 2 groups but 
additional safety data provided were limited.26,27
The limitations of this study are that information on initiation of cooling during transport of 
neonates to the Neonatal Research Network centers was not known nor was the frequency of 
electroencephalographic seizures at random assignment. There were no adjustments made 
for multiple comparisons.
Currently deeper or longer cooling are not administered as part of usual care; however, there 
are a few reports of core temperatures recorded below 33.5°C during therapeutic 
hypothermia.28–30 In addition, a single report has been published regarding cooling 
continued beyond 72 hours.31 Our findings suggest that cooling for 120 hours or to 32.0°C, 
or both, may be deleterious. For clinicians using hypothermia, we suggest that deviations 
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from the current published regimen of cooling of 33.0°C to 34.0°C for 72 hours have the 
potential for harm.19
Conclusions
Among neonates of at least 36 weeks’ gestational age with moderate or severe hypoxic 
ischemic encephalopathy, deeper cooling or longer duration of cooling compared with 
hypothermia at 33.5°C for 72 hours did not reduce NICU death. These results have 
implications for patient care and the design of future trials.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow of Neonates Through the Trial
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Figure 2. Survival for the Hypothermia Groups
Dotted lines represent day 3 (72 hours) and day 5 (120 hours).
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Figure 3. 
Mean (SD) Esophageal Temperatures During the Intervention Period
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Table 1
Maternal and Neonatal Characteristicsa
Duration of Cooling, No. (%) Depth of Cooling, No. (%)
72 h (n = 185) 120 h (n = 179) 33.5°C (n = 191) 32.0°C (n = 173)
Maternal
Raceb
 Black     57 (31)     57 (33)     61 (32)     53 (31)
 White   116 (63)   103 (59)   115 (61)   104 (62)
 Otherb     11 (6)     14 (8)     13 (7)     12 (7)
Maternal age, mean (SD), y  27.9 (6.7)  27.9 (6.9)  28.3 (6.5)  27.4 (7.1)
Married     95 (52)     91 (51)   102 (54)     84 (49)
Gravida, median (IQR)       2 (1–3)       2 (1–3)       2 (1–3)       2 (1–3)
Parity, median (IQR)       1 (1–2)       1 (1–3)       1 (1–3)       1 (1–2)
Pregnancy complications
Chronic hypertension     37 (20)     36 (20)     35 (18)     38 (22)
 Antepartum hemorrhage     23 (13)     17 (10)     21 (11)     19 (11)
 Thyroid dysfunction     11 (6)       3 (2)       6 (3)       8 (5)
 Diabetes     21 (11)     25 (14)     22 (12)     24 (14)
Intrapartum complications
 Fetal decelerations   142 (77)   140 (80)   149 (79)   133 (77)
 Cord prolapse, rupture, compression     27 (15)     22 (12)     29 (15)     20 (12)
 Uterine rupture     11 (6)     11 (6)       9 (5)     13 (8)
 Maternal pyrexia (≥37.6°C)     23 (13)     18 (10)     17 (9)     24 (14)
 Shoulder dystocia     14 (8)     15 (8)     14 (7)     15 (9)
 Maternal hemorrhage     27 (15)     28 (16)     30 (16)     25 (14)
Rupture of membranes (spontaneous or induced)
 No rupture     46 (26)     51 (30)     56 (30)     41 (25)
 ≤18h   116 (64)   100 (58)   112 (60)   104 (63)
 >18 h     18 (10)     20 (12)     18 (10)     20 (12)
Rupture of membranes, h
 Mean (SD)  11.8 (20.4)  10.5 (16.4)  11.4 (17.6)  10.9 (19.5)
 Median (IQR)    7.6 (2.5–14.7)    5.9 (2.0–13.7)    6.4 (2.4–14.1)    7.3 (1.6–14.6)
Emergency cesarean delivery   117 (63)   114 (64)   119 (62)   112 (65)
Neonatal
 Age at randomization, h    5.0 (1.1)    4.9 (1.4)    4.9 (1.1)    4.9 (1.4)
 Transferred from birth hospital   119 (64)   115 (64)   124 (65)   110 (64)
 Male   105 (57)   107 (60)   103 (54)   109 (63)
Apgarscore ≤5
 5 min after birth   155 (84)   151 (85)   162 (85)   144 (84)
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Duration of Cooling, No. (%) Depth of Cooling, No. (%)
72 h (n = 185) 120 h (n = 179) 33.5°C (n = 191) 32.0°C (n = 173)
 10 min after birth   107 (66)   116 (72)   115 (70)   108 (68)
Birth weight, g 3293 (538) 3427 (651) 3292 (608) 3432 (582)
Length, cm  50.5 (2.9)  50.8 (3.1)  50.5 (2.9)  50.8 (3.1)
Head circumference, cm  34.0 (1.9)  34.3 (1.7)  34.0 (1.6)  34.2 (2.0)
Intubation in delivery room   143 (77)   143 (80)   152 (80)   134 (78)
Continued resuscitation at 10 min   155 (84)   160 (90)   168 (88)   147 (85)
Time to spontaneous respiration >10 min     72 (41)     78 (47)     83 (47)     67 (41)
Cord blood
 pH 6.94 (0.2) 6.95 (0.2) 6.94 (0.2) 6.95 (0.2)
 Base deficit  16.2 (7.8)  15.9 (6.7)  16.1 (7.5)  16.0 (7.0)
Seizuresc     48 (26)     57 (32)     58 (30)     47 (27)
 Moderate encephalopathy   144 (78)   136 (76)   152 (80)   128 (74)
 Severe encephalopathy     41 (22)     43 (24)     39 (20)     45 (26)
Inotropic supportc     42 (23)     34 (19)     35 (18)     41 (24)
Anticonvulsantsc     32 (19)     25 (17)     31 (19)     26 (17)
Abbreviation: IQR, interquartile range.
a
Percentages are based on the number of mothers or neonates for whom data were available. Because of rounding, not all percentages sum to 100.
bOther race includes American Indian or Alaskan Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial.
c
Data are for this characteristic at the time of randomization.
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